Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Robo.ai is trying to move from a failed smart-EV revenue base into an AI robotics, intelligent hardware and asset platform. The filings show FY2025 revenue of only $0.95 million, a $167.3 million net loss, $4.1 million of cash, $124.6 million of liabilities, n
OpenAeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
OpenQuantumScape reported no revenue in FY2025 or Q1 2026, a FY2025 net loss of $435.1 million and Q1 2026 operating cash use of $59.5 million. The thesis depends on technology milestones, partner validation, manufacturing scale-up, cash runway and dilution contro
OpenGE Vernova reported FY2025 revenue of $38.1 billion, FY2025 operating income of $1.4 billion, FY2025 operating cash flow of $5.0 billion and Q1 2026 revenue of $9.3 billion. The setup depends on grid demand, power-equipment execution, contract liabilities, mar
OpenCaterpillar reported FY2025 revenue of $67.6 billion, FY2025 operating income of $11.2 billion and Q1 2026 revenue of $17.4 billion. The thesis is dealer-network strength, margin durability and cash generation through an industrial cycle.
OpenDeere reported FY2025 revenue of $45.7 billion and Q1 2026 revenue of $9.6 billion. The thesis depends on farm-cycle demand, precision technology, dealer discipline, margins and financing credit quality.
OpenAshford Hospitality Trust reported better Q1 comparable RevPAR and hotel EBITDA, but the Q1 2026 10-Q includes going-concern doubt, $1.9 billion of near-term non-recourse loan maturities, defaulted loans and suspended preferred dividends. AHT is a high-risk lo
OpenAscent Industries is trying to turn a cash-rich post-divestiture shell into a focused specialty chemicals platform, with Q1 revenue growth, no revolver debt, aggressive buybacks, a Midwest packaging-chemistry acquisition, and unresolved proof gates around marg
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAIFU still has a large China insurance distribution platform, with 42,170 registered agents and 313 sales outlets, but the 2025 Form 20-F shows a severe revenue and asset-quality reset before a 2026 acquisition added dark tea inventory, heavy share issuance an
OpenFirefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings
OpenAGCO is a global farm-equipment maker with Fendt, Massey Ferguson, PTx and Valtra, but the current thesis is a cycle and execution test: FY2025 sales fell 13.5%, Q1 2026 sales rebounded 14.3%, Europe carried segment profit, and PTx precision agriculture must p
OpenForafric owns real Morocco and West Africa milling assets, but the current stock story is a very-high-risk turnaround: H1 revenue collapsed, the 2025 annual report is late, going-concern language is live, and the newest strategic pivot needs hard proof.
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAebi Schmidt is a newly enlarged specialty-vehicle platform with snowplows, municipal equipment, airport equipment, commercial truck bodies, Shyft merger synergies, a $1.3 billion backlog, and a leverage target that needs cash conversion.
OpenAditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenADTRAN's fiber and optical-networking rebound is finally visible in official numbers, but the next decision point is whether gross margin, cash conversion, debt, and Adtran Networks obligations let common shareholders keep the upside.
OpenAdient has the footprint OEMs need and the revenue scale investors notice, but the stock case comes down to whether EMEA repair, Asia pricing, launch costs, tariffs, and working capital finally let margin catch up with sales.
OpenAcacia is a public acquisition/operator vehicle with energy wells, industrial printers, Deflecto manufacturing, patent licensing, life-sciences remnants, and a large capital base. The question is whether those parts compound per-share value or bury it in compl
OpenABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.
Open